

Chiesi Acquires New Manufacturing Site in Nerviano (Milan) with a Strategic €430 Million Investment To 2030 to Drive Global Growth

Published On: 2025-03-26 12:00

Category: #Corporate



- The project is part of the Group's industrial plan to support its global growth
- The site will specialize in the production of sterile biological products, DPI and carbon minimal inhalers for the treatment of respiratory diseases, with a primary focus on the latter
- The redevelopment of the facility and its surrounding area will be centered on innovation and sustainability criteria

Milan, March 27th, 2025 – **Chiesi Group**, a global biopharmaceutical company headquartered in Parma, Italy, has announced a major investment in **Nerviano** (Milan, Italy), with the construction of a new facility for the production of its therapeutic solutions. The project entails the revitalization of this historical production site, first established in 1965 as an oncology research centre for Farmitalia Carlo Erba and subsequently subjected to several ownership changes, until its closure in 2024. The facility will be primarily dedicated to manufacturing **carbon minimal inhalers**, reinforcing the company's commitment to both patients' health and sustainable healthcare solutions. **Dry powder inhalers and sterile biological products** will also be developed in Nerviano.

- The **€430 million investment**, spread between 2025 and 2030, will fund the redevelopment of a **124,000-square-meter** industrial area, transforming it into an international center of excellence. This initiative is part of the Group's global industrial strategy, which includes ongoing investments in its facilities in **Parma (Italy)** and **Blois (France)** and operations in **Santana de Parnaíba (Brazil)** to meet the growing needs of people living with respiratory conditions. The objective is to **support the company's growth and its goal of achieving Net Zero emissions by 2035**.

The redevelopment will modernize the existing site, originally built in the 1980s, turning it into a next-generation production center. Once fully operational, the site will feature over **3,000 square meters of laboratory space** and a **photovoltaic park** with an installed capacity sufficient to ensure the plant's energy self-sufficiency. Adjacent to the industrial facility, a **20,000-square-meter wooded area** will undergo a regeneration project.

Beyond its environmental and technological advancements, the investment will deliver tangible benefits to the local community. The site is expected to **create approximately 300 new jobs by 2029**, stimulating economic growth in the region.

*"We chose Nerviano for its strategic location and the potential of the industrial area, which we will transform into a center of excellence for the production of next-generation inhalers," said **Giuseppe Accogli**, CEO of Chiesi Group. "This investment strengthens our presence in Italy and Europe, consolidates our leadership in the sector, and creates new growth opportunities for the local community. It also complements our significant investments in the Parma area, notably our recent Biotech Center launch."*

About Chiesi Group

Chiesi is research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment.

By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi's commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.

With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group's research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

Contacts for Media:

Gruppo Chiesi

Laura Vergani, Senior Vice President, Global Communications & Public Affairs

e-mail: mediarelations@chiesi.com

Davide Paterlini, Global External Communications Sr. Manager

mobile +39 345.7983132, e-mail: d.paterlini@chiesi.com